Devonian's Thykamine Shows Dose-Dependent Anti-MASH Effects in Liver Gene Study

Event summary

  • Devonian reported additional molecular data from its STAM mouse model study, showing Thykamine™ significantly reduced liver disease progression, inflammation, and fibrosis in a dose-dependent manner.
  • Gene expression analysis revealed Thykamine™ down-regulated multiple fibrosis and inflammation-related genes by 80–90% at the maximum tested dose.
  • The study evaluated 29 genes, including 13 fibrosis-related, 5 inflammation-related, and 11 involved in both pathways.
  • Regional variation in Thykamine™'s molecular activity was observed between the caudal and lateral liver lobes.
  • The complete gene expression results will be included in a planned scientific publication of the STAM MASH preclinical study.

The big picture

Devonian's findings strengthen Thykamine™'s potential as a multi-targeting treatment for fibroinflammatory diseases, expanding its reach beyond dermatology and inflammatory bowel diseases to include hepatic conditions like MASH. The global MASH treatment market is rapidly growing, driven by rising rates of obesity and metabolic syndrome, presenting a significant opportunity for Devonian. The company's focus on prescription botanical drug products aligns with favorable regulatory pathways, potentially accelerating its development timeline.

What we're watching

Clinical Translation
Whether the molecular effects observed in the STAM mouse model will translate to human clinical trials for MASH.
Market Positioning
How Devonian positions Thykamine™ in the rapidly growing MASH treatment market, projected to reach $31.76 billion by 2033.
Regulatory Pathway
The pace at which Devonian advances Thykamine™ through regulatory approvals, leveraging the FDA's favorable guidelines for prescription botanical drug products.

Related topics

Biotechnology